Treatment of heterozygous familial hypercholesterolemia: what does the future hold?
Sign Up to like & getrecommendations! Published in 2020 at "Expert Review of Clinical Pharmacology"
DOI: 10.1080/17512433.2020.1839417
Abstract: ABSTRACT Introduction Heterozygous familial hypercholesterolemia (heFH) is a common metabolic disease associated with increased cardiovascular risk. Despite treatment with the currently available lipid-lowering agents (statins, ezetimibe, and proprotein convertase subtilisin/kexin type 9 inhibitors), a substantial… read more here.
Keywords: treatment; patients hefh; heterozygous familial; lipid lowering ... See more keywords